One of the most highly-cited journals in cardiology has retracted a paper less than a month after publishing it in response to criticism first posted on Twitter.
The article, “Short-term and long-term effects of a loading dose of atorvastatin before percutaneous coronary intervention on major adverse cardiovascular events in patients with acute coronary syndrome: a meta-analysis of 13 randomized controlled trials,” was published online January 3 in the European Heart Journal (EHJ). Its authors purported to analyze clinical trials of patients who were given a loading dose of atorvastatin, a cholesterol medication, before undergoing cardiac catheterization.
How closely the study authors adhered to their own methods came under question on January 8, when Ricky Turgeon, a cardiology pharmacist, posted a series of tweets in which he claimed some of the studies included in the analysis either did not test the drug in patients undergoing the procedure — referred to as PCI — or patients had not all been diagnosed with acute coronary syndrome, commonly known as a heart attack. With many of the trials included in the analysis not abiding by the predefined inclusion criteria, the study’s conclusions are unreliable, argued Turgeon.Continue reading Should journals credit eagle-eyed readers by name in retraction notices?
Anita Bandrowski, a neuroscientist at the University of California, San Diego, works on tools to improve the transparency and reproducibility of scientific methods. (Her work on Research Resource Identifiers, or RRIDs, has been previously featured on Retraction Watch.) This week, Bandrowski and colleagues — including Amanda Capes-Davis, who chairs the International Cell Line Authentication Committee — published a paper in eLife that seeks to determine whether these tools are actually influencing the behavior of scientists, in this case by reducing the number of potentially erroneous cell lines used in published studies.
Such issues may affect thousands of papers. Among more than 300,000 cell line names in more than 150,000 articles, Bandrowski and her colleagues “estimate that 8.6% of these cell lines were on the list of problematic cell lines, whereas only 3.3% of the cell lines in the 634 papers that included RRIDs were on the problematic list,” suggesting “that the use of RRIDs is associated with a lower reported use of problematic cell lines.”
Retraction Watch spoke with Bandrowski about the role of these tools in the larger movement to improve transparency and reproducibility in science, and whether meta-scientific text-mining approaches will gain traction in the research community.